Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer

[1]  E. Monti,et al.  Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. , 2007, Cancer letters.

[2]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[3]  R. Gust,et al.  Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. , 2007, Anti-cancer agents in medicinal chemistry.

[4]  H. Choy.  Satraplatin: an orally available platinum analog for the treatment of cancer , 2006, Expert review of anticancer therapy.

[5]  L. Collette,et al.  Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.

[6]  S. Sundar,et al.  Platinum-based chemotherapy in metastatic breast cancer: current status. , 2004, Cancer treatment reviews.

[7]  W. Rose,et al.  Preclinical antitumor activity of orally administered platinum (IV) complexes , 2004, Cancer Chemotherapy and Pharmacology.

[8]  K. Kolarić,et al.  Carboplatin activity in untreated metastatic breast cancer patients — results of a phase II study , 2004, Cancer Chemotherapy and Pharmacology.

[9]  K. Kolarić,et al.  Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[10]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[11]  Miguel Martín,et al.  Platinum compounds in the treatment of advanced breast cancer. , 2001, Clinical breast cancer.

[12]  N. Saijo,et al.  Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. , 2000, Japanese journal of clinical oncology.

[13]  R. Weichselbaum,et al.  The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.

[14]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[15]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[16]  L. Kèlland,et al.  Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  D. Talbot,et al.  Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Kèlland,et al.  Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. , 1993, Cancer research.

[19]  E. Adrover,et al.  Carboplatin: an active drug in metastatic breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Díaz-Rubio,et al.  Phase II study of carboplatin in advanced breast cancer: preliminary results. , 1991, Seminars in oncology.

[21]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[22]  G. Sledge,et al.  Cisplatin as first-line therapy for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Harrap.  Preclinical studies identifying carboplatin as a viable cisplatin alternative. , 1985, Cancer treatment reviews.